Cell culture model predicts human disease: Altered expression of junction proteins and matrix metalloproteinases in cervical dysplasia

BMC Clinical Pathology

Volumn 12, Issue , 2012, Pages

  Kivi, Niina ^a   Rönty, Mikko ^b   Tarkkanen, Jussi ^b   Auvinen, Petri ^c   Auvinen, Eeva ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Cadherin; Catenin; CIN; Cytokeratin; E5; HPV; Microarray; MMP

Indexed keywords

BETA CATENIN; COLLAGEN; CYTOKERATIN 18; CYTOKERATIN 8; LAMININ; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 16; PROTEIN P16; UVOMORULIN;

ARTICLE; CARCINOGENESIS; CELL CULTURE; CONDYLOMA; CONTROLLED STUDY; E5 ONCOGENE; EPITHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; ONCOGENE; PREDICTION; PROTEIN EXPRESSION; RISK; TISSUE MICROARRAY; UTERINE CERVIX CANCER; UTERINE CERVIX DYSPLASIA; UTERINE CERVIX EPITHELIUM; WART VIRUS;

EID: 84864511932     PISSN: None     EISSN: 14726890     Source Type: Journal    
DOI: 10.1186/1472-6890-12-9     Document Type: Article

References (43)

1. Papillomaviruses in the causation of human cancers-a brief historical account. zur Hausen H, Virology 2009 384 260 265 10.1016/j.virol.2008.11.046 19135222
2. Cellular transformation by human papillomaviruses: lessons learned by comparing high- and low-risk viruses. Klingelhutz AJ, Roman A, Virology 2012 424 77 98 10.1016/j.virol.2011.12.018 22284986
3. Enhancement of EGF- and PMA-mediated MAP kinase activation in cells expressing the human papillomavirus type 16 E5 protein. Crusius K, Auvinen E, Alonso A, Oncogene 1997 15 1437 1444 10.1038/sj.onc.1201312 9333019 (Pubitemid 27437833)
4. The human papillomavirus type 16 E5-protein modulates ligand-dependent activation of the EGF receptor family in the human epithelial cell line HaCaT. Crusius K, Auvinen E, Steuer B, Gaissert H, Alonso A, Exp Cell Res 1998 241 76 83 10.1006/excr.1998.4024 9633515 (Pubitemid 28366581)
5. The E5 gene of HPV-16 enhances keratinocyte immortalization by full-length DNA. Conrad Stöppler M, Straight SW, Tsao G, Schlegel R, McCance DJ, Virology 1996 223 251 254 10.1006/viro.1996.0475 8806560 (Pubitemid 26302066)
6. The E5 oncoprotein of human papillomavirus type 16 transforms fibroblasts and effects the downregulation of the epidermal growth factor receptor in keratinocytes. Straight SW, Hinkle PM, Jewers RJ, McCance DJ, J Virol 1993 67 4521 4532 8392596 (Pubitemid 23215930)
7. The human papillomavirus type 16 E5 oncoprotein inhibits epidermal growth factor trafficking independently of endosome acidification. Suprynowicz FA, Krawcyk E, Hebert JD, Sudarshan SR, Simic V, Kamonjoh CM, Schlegel R, J Virol 2010 84 10619 10629 10.1128/JVI.00831-10 20686024
8. A role for HPV16 E5 in cervical carcinogenesis. Maufort JP, Shai A, Pitot HC, Lambert PF, Cancer Res 2010 70 2924 2931 10.1158/0008-5472.CAN-09-3436 20332225
9. The cadherin-catenin adhesion system in signaling and cancer. Conacci-Sorrell M, Zhurinsky J, Ben-Zeev A, J Clin Invest 2002 109 987 991 11956233 (Pubitemid 34408571)
10. Genes involved in cell adhesion, cell motility and mitogenic signaling are altered due to HPV 16 E5 protein expression. Kivi N, Greco D, Auvinen P, Auvinen E, Oncogene 2008 27 2532 2541 10.1038/sj.onc.1210916 17982485 (Pubitemid 351550881)
11. Human papillomavirus 16 E5 modulates the expression of host microRNAs. Greco D, Kivi N, Qian K, Leivonen SK, Auvinen P, Auvinen E, PLoS One 2011 6 21646 10.1371/journal.pone.0021646 21747943
12. Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. Hojilla CV, Mohammed FF, Khokha R, Br J Cancer 2003 89 1817 1821 10.1038/sj.bjc.6601327 14612884 (Pubitemid 37533251)
13. Human papillomavirus type 16 E5 protein affects cell-cell communication in an epithelial cell line. Oelze I, Kartenbeck J, Crusius K, Alonso A, J Virol 1995 69 4489 4494 7769709
14. Using an immortalized cell line to study the HPV life cycle in organotypic raft cultures. Lambert PF, Ozbun MA, Collins A, Holmgren S, Lee D, Nakahara T, Methods Mol Med 2005 119 141 155 16353335
15. Differential expression of the extra domain-containing form of cellular fibronectin in human placentas at different stages of maturation. Virtanen I, Laitinen L, Vartio T, Histochem Cell Biol 1988 90 25 30 10.1007/BF00495702
16. Uterine cervical carcinoma: Role of matrix metalloproteinases. Libra M, Scalisi A, Vella N, Clementi S, Sorio R, Stivala F, Spandidos DA, Mazzarino C, Int J Oncol 2009 34 897 903 19287946
17. Increased expression and activation of gelatinolytic matrix metalloproteinases is associated with the progression and recurrence of human cervical cancer. Sheu BC, Lien HC, Ho HN, Lin HH, Chow SN, Huang SC, Hsu SM, Cancer Res 2003 63 6537 6542 14559848
18. Clinical significance of matrix metalloproteinase-2 in cancer of uterine cervix: A semiquantitative study of immunoreactivities using tissue array. Wang PH, Ko JL, Tsai HT, Yang SF, Han CP, Lin LY, Chen GD, Gynecol Oncol 2008 108 533 542 10.1016/j.ygyno.2007.11.018 18177928
19. Expression of membrane type 1 matrix metalloproteinase is associated with cervical carcinoma progression and invasion. Zhai Y, Hotary KB, Nan B, Bosch FX, Muñoz N, Weiss SJ, Cho KR, Cancer Res 2005 65 6543 6550 10.1158/0008-5472.CAN-05-0231 16061633 (Pubitemid 41060689)
20. The role of matrix metalloproteinases in squamous cell carcinomas of the head and neck. Werner JA, Rathcke IO, Mandic R, Clin Exp Metastasis 2002 4 275 282 (Pubitemid 34606752)
21. Enhanced production and activation of matrix metalloproteinase-7 (matrilysin) in human endometrial carcinomas. Ueno H, Yamashita K, Azumano I, Inoue M, Okada Y, Int J Cancer (Pred Oncol) 1999 84 470 477 10.1002/(SICI)1097- 0215(19991022)84:5<470::AID-IJC4>3.0.CO;2-D
22. Expression and tissue localization of matrix metalloproteinase-7 (matrilysin) in human gastric carcinomas. Implications for vessel invasion and metastasis. Yamashita K, Azumano I, Mai M, Okada Y, Int J Cancer (Pred Oncol) 1998 79 187 194 10.1002/(SICI)1097-0215(19980417)79:2<187::AID-IJC15>3.0. CO;2-7 (Pubitemid 28201692)
23. Expression pattern of matrix metalloproteinases in human gynecological cancer cell lines. Schröpfer A, Kammerer U, Kapp M, Dietl J, Feix S, Anacker J, BMC Cancer 2010 10 553 10.1186/1471-2407-10-553 20942921
24. Matrix metalloproteinase-2 (MMP-2) is present in the nucleus of cardiac myocytes and is capable of cleaving poly(ADP-ribose) polymerase (PARP) in vitro. Kwan JA, Schulze CJ, Wang W, Leon H, Sariahmetoglu M, Sung M, Sawicka J, Sims DE, Sawicki G, Schulz R, FASEB J 2004 10.1096/fj.02-1202fje
25. Matrix metalloproteinase 3 is present in the cell nucleus and is involved in apoptosis. Si-Tayeb K, Monvoisin A, Mazzocco C, Lepreux S, Decossas M, Cubel G, Taras D, Blanc JF, Robinson DR, Rosenbaum J, Am J Pathol 2006 169 1390 1401 10.2353/ajpath.2006.060005 17003494 (Pubitemid 351194372)
26. Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130. Campisi Hegan D, Lu Y, Stachelek GC, Crosby ME, Bindra RS, Glazer PM, Proc Natl Acad Sci USA 2010 107 2201 2206 10.1073/pnas.0904783107 20133863
27. Expression of simple epithelial keratins 8 and 18 in epidermal neoplasia. Markey AC, Lane EB, Churchill LJ, MaDonald DM, Leigh IM, J Invest Dermatol 1991 97 763 770 10.1111/1523-1747.ep12486607 1717607
28. Gene profiling in Pap-cell smears of high-risk human papillomavirus- positive squamous cervical carcinoma. Manavi M, Hudelist G, Fink-Retter A, Gschwandtler-Kaulich D, Pischinger K, Czerwenka K, Gynecol Oncol 2007 105 418 426 10.1016/j.ygyno.2006.12.032 17306351 (Pubitemid 46590336)
29. Expression of cytokeratin polypeptides in human papillomavirus (HPV) lesions of the uterine cervix: 1. Syrjänen S, Cintorino M, Armellini D, DelVecchio MT, Leocini P, Bugnoli M, Pallini V, Silvestri S, Tosi P, Mäntyjärvi R, Syrjänen K, Relationship to grade of CIN and HPV type. Int J Gynecol Pathol 1988 7 23 38 (Pubitemid 18070445)
30. Cytokeratin 8/18 expression indicates a poor prognosis in squamous cell carcinomas of the oral cavity. Fillies T, Werkmeister R, Packeisen J, Brandt B, Morin P, Weingart D, Joos U, Buerger H, BMC Cancer 2006 6 10 10.1186/1471-2407-6-10 16412231
31. Malignant progression of an HPV16-immortalized human keratinocyte cell line (HPKIA) in vitro. Dürst M, Seagon S, Wanschura S, zur Hausen H, Bullerdiek J, Cancer Genet Cytogenet 1995 85 105 112 10.1016/0165-4608(95)00155- 7 8548732 (Pubitemid 26030366)
32. Vanden Broeck D, Van Marck EA, Bogers JJ: Correlation between laminin-5 immunohistochemistry and human papillomavirus status in squamous cervical carcinoma. Boulet GAV, Schrauwen I, Sahebali S, Horvath C, Depuydt CE, Vereecken A, J Clin Pathol 2007 60 896 901 17660333 (Pubitemid 47234436)
33. Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells. Martinez I, Gardiner AS, Board KF, Monzon FA, Edwards RP, Khan SA, Oncogene 2008 27 2575 2582 10.1038/sj.onc.1210919 17998940 (Pubitemid 351550884)
34. Jansen-van Rhijn CM, Warnaar SO, Fleuren GJ, Litvinov SV: Changing roles of cadherins and catenins during progression of squamous intraepithelial lesions in the uterine cervix. de Boer CJ, van Dorst E, van Krieken H, Am J Pathol 1999 155 505 515 10.1016/S0002-9440(10)65146-2 10433943 (Pubitemid 29370400)
35. E-cadherin, CD44 and CD44v6 in squamous intraepithelial lesions and invasive carcinomas of the uterine cervix: an immunohistochemical study. Faleiro-Rodrigues C, Lopes C, Pathobiol 2004 71 329 336 10.1159/000081729 (Pubitemid 40082314)
36. García-Carrancá: Abnormal distribution of E-cadherin and β-catenin in different histologic types of cancer of the uterine cervix. Rodríguez-Sastre MA, González-Maya L, Delgado R, Lizano M, Tsubaki G, Mohar A, Gynecol Oncol 2005 97 330 336 10.1016/j.ygyno.2004.12.062 15863126 (Pubitemid 40614872)
37. E-cadherin expression during progression of squamous intraepithelial lesions in the uterine cervix. Kaplanis K, Kiziridou A, Liberis V, Destouni C, Galazios G, Eur J Gynaecol Oncol 2005 26 608 610 16398219 (Pubitemid 43028053)
38. E-cadherin and catenins in early squamous cervical carcinoma. Van de Putte G, Kristensen GB, Baekelandt M, Lie AK, Holm R, Gynecol Oncol 2004 94 521 527 10.1016/j.ygyno.2004.05.046 15297198 (Pubitemid 39028907)
39. HPV-PathogenISS Study Group: Down-regulation of E-cadherin is closely associated with progression of cervical intraepithelial neoplasia (CIN), but not with high-risk human papillomavirus (HPV) or disease outcome in cervical cancer. Branca M, Giorgi C, Ciotti M, Santini D, Di Bonito L, Costa S, Benedetto A, Bonifacio D, Di Bonito P, Paba P, Accardi L, Mariani L, Syrjänen S, Favalli C, Syrjänen K, Eur J Gynaecol Oncol 2006 27 215 223 16800245 (Pubitemid 43953413)
40. Deregulation by E-cadherin by human papillomavirus is not confined to high-risk, cancer-causing types. Leong CM, Doorbar J, Nondl I, Yoon HS, Hibma MH, Br J Dermatol 2010 163 1253 1263 10.1111/j.1365-2133.2010.09968.x 20698848
41. High-risk HPV infection and CIN grade correlates to the expression of c-myc, CD4+, FHIT, E-cadherin, Ki-67, and p16INK4a. Samir R, Asplund A, Tot T, Pekar G, Hellberg D, J Lower Gen Tract Dis 2011 15 280 286 10.1097/LGT. 0b013e318215170c
42. MT1-MMP and MMP-7 in invasion and metastasis of human cancers. Shiomi T, Okada Y, Cancer Metast Rev 2003 22 145 152 10.1023/A:1023039230052 (Pubitemid 36561054)
43. The metalloproteinase matrilysin is a target of β-catenin transactivation in intestinal tumors. Crawford HC, Fingleton BM, Rudolph-Owen LA, Heppner Goss KJ, Rubinfeld B, Polakis P, Matrisian LM, Oncogene 1999 18 2883 2891 10.1038/sj.onc.1202627 10362259 (Pubitemid 29250878)